Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2016-05-17 Regulatory Filings
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV, for the month of May 2016. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Form 20-F or 40-F, often including press releases or other announcements. The document references an attached press release (Exhibit 99.1) but does not contain detailed financial statements or substantive financial data itself. The document length is short (1482 characters), and it primarily serves as a report of a press release filing rather than a full report. According to the classification rules, such filings are best categorized under Regulatory Filings (RNS) as they do not constitute full reports like Annual Reports (10-K) or Interim Reports (IR).
2016-05-17 English
Listing of existing shares on Euronext Brussels & Amsterdam
Report Publication Announcement Classification · 98% confidence The document is a short announcement dated May 17, 2016, regarding the listing of shares on Euronext Brussels & Amsterdam following the approval of a listing prospectus by the Belgian Financial Services and Markets Authority. It details the admission to trading of shares subscribed to by Gilead. The text is brief (under 5,000 characters) and explicitly mentions that a copy of the listing prospectus is available on their website. This structure—a brief announcement stating that a formal document (prospectus/filing) has been published or is available—fits the definition of a Report Publication Announcement (RPA). It is not the full prospectus itself, nor is it a standard regulatory filing like a 10-K or an earnings release. It is an announcement about the publication/listing event.
2016-05-17 English
Toelating bestaande aandelen op Euronext Brussel & Amsterdam
Delisting Announcement Classification · 99% confidence The document is dated May 17, 2016, and announces that 6,760,701 shares, subscribed by Gilead, were admitted for trading on Euronext Brussels and Amsterdam following the approval of a listing prospectus by the Belgian Financial Services and Markets Authority (FSMA). This announcement concerns the admission of existing shares to trading, which is a corporate action related to capital structure or listing status. It is not a full annual report (10-K), an earnings release (ER), or a standard quarterly report (IR). It is a specific announcement regarding the listing/trading of shares, which falls under Capital/Financing Update (CAP) or potentially a general Regulatory Filing (RNS). Since it specifically details the admission of shares following a prospectus approval, it relates directly to capital structure changes or financing events. Given the options, 'Capital/Financing Update' (CAP) is the most appropriate fit for an announcement detailing the admission of a large block of shares to trading, even if it's not a new issuance, as it impacts the publicly traded capital base. However, the core event is the admission to trading following regulatory approval, which is often categorized as a general regulatory announcement if a more specific code isn't available. Comparing CAP (fundraising, financing activities, capital structure changes) and RNS (general regulatory announcements/fallback), the event is highly specific to the listing/trading of shares. Since the document is short and announces an event rather than providing a comprehensive report, and it deals with the listing of shares, it aligns best with 'Capital/Financing Update' (CAP) as it directly impacts the tradable capital structure, or potentially 'Share Issue/Capital Change' (SHA), although this is an admission of previously subscribed shares rather than a new issue. Given the context of listing approval, CAP seems slightly broader and more fitting than SHA (which usually implies a new issuance or split). If it were purely a notice of a regulatory filing, RPA or RNS would apply, but this is the substance of the regulatory action's result. I will classify it as CAP due to the direct impact on the publicly traded share base following a prospectus approval.
2016-05-17 Dutch
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV, pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Forms 20-F or 40-F. The document references an attached press release dated May 9, 2016, but the text itself is short (1479 characters) and primarily serves as a report submission notice rather than containing substantive financial data or detailed report content. According to the classification rules, such filings that are brief and serve as regulatory announcements or submissions without detailed financial or management information should be classified as Regulatory Filings (RNS).
2016-05-11 English
Galapagos starts Phase 1 study with potentiator GLPG2451 for CF
Regulatory Filings Classification · 95% confidence The document is a press release dated May 9, 2016, announcing the start of a Phase 1 clinical study for a drug candidate (GLPG2451) and triggering a milestone payment from AbbVie. It details ongoing clinical programs (Phase 1, Phase 2) for various compounds related to cystic fibrosis. This content is characteristic of an announcement detailing operational and research progress, often released outside of mandatory periodic financial reports (like 10-K or IR). It is not a full financial report (10-K or IR), an earnings release (ER) focusing on period results, a proxy statement (DEF 14A), or a transcript (CT). Since it is a specific, time-sensitive operational update that doesn't fit the other specific categories (like M&A, Dividend, Capital Change), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for official company announcements not covered elsewhere, or potentially an Investor Presentation (IP) if it were structured as slides, but as a text release, RNS is more appropriate for general news updates.
2016-05-10 English
Galapagos starts Phase 1 study with potentiator GLPG2451 for CF
Earnings Release Classification · 95% confidence The document is a press release dated May 9, 2016, announcing the start of a Phase 1 clinical trial for a drug candidate (GLPG2451) for Cystic Fibrosis (CF) and mentioning a milestone payment received from AbbVie. It details ongoing clinical programs (Phase 1, Phase 2) for various drug candidates (GLPG1837, GLPG2222, etc.) and provides company background and contact information. This structure—announcing specific operational/clinical progress, financial milestones related to partnerships, and future expectations—is characteristic of an Earnings Release (ER) or a general operational update. Since it focuses on clinical trial initiation and partnership payments rather than comprehensive quarterly financials (which would be an IR) or just management changes (MANG), it fits best as an initial announcement of key operational and financial highlights related to R&D progress. Given the context of biotech/pharma reporting, this type of announcement, which is often released concurrently with or shortly before formal quarterly results, is classified as an Earnings Release (ER) if it contains key financial/operational metrics, or potentially a Regulatory Filing (RNS) if it were less specific. However, the content strongly suggests an 'Earnings Release' (ER) or a significant operational update that functions similarly to an ER by highlighting key performance indicators (trial starts, milestone payments). It is not a full report (10-K, IR), a presentation (IP), or a simple notice (RPA, DIV). I will classify it as ER. Q2 2016
2016-05-10 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.